NCT01475643View on ClinicalTrials.gov

Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.

PHASE3CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

June 2, 2017

Study Completion Date

July 31, 2017

Conditions

Cataract

Interventions

DRUG

Loteprednol etabonate

1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.

DRUG

Prednisolones acetate

1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.

Trial Locations (1)

14609

Bausch & Lomb Inc, Rochester

All Listed Sponsors

lead

Bausch & Lomb Incorporated

INDUSTRY

NCT01475643 - Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children. | Biotech Hunter | Biotech Hunter